TransCode shares Phase 1a trial data for TTX-MC138 at ESMO 2026
Tweet Send to a Friend
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) presented Phase 1a clinical trial results for its drug candidate TTX-MC138 at the European Society ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




